Experience in preparing obese patients for infertility treatment


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective. To study whether Reduxin Forte can be used in obese patients planning IVF. Subjects and methods. Thirty women with grade 1 obesity were examined and treated. Along with physical exercises and diet, Reduxin Forte (sibutramine 10-15 mg/day + metformin 850 mg/day) was used in the patients for 3 months. Anthropometric and carbohydrate metabolic parameters and the oxidative stress marker 8-0H-deoxyguanosine (8-0HdG) were estimated before and after treatment. Results. Prior to and following treatment, there were reductions in weight by 10.8% (90.597+5.79 vs. 80.773+5.58 kg; p = 0.017), BMI (33.324+1.53 vs. 29.719+1.55; p = 0.002), waist (96.733+3.92 vs. 89.133+3.91 cm; p = 0.008) and hip (114.067+4.40 vs. 107.733+3.54 cm; p = 0.028) circumferences. It should be emphasized that there were also decreases in insulin levels (15.271+2.67vs. 10.049+1.72pU/ml;p = 0.002), H0MA index (3.673+0.67 vs. 2.28+0.41; p < 0.001), and the levels of the oxidative stress marker 8-0HdG (0.361+0.082 vs. 0.240+0.029 ng/ml; p = 0.007). Conclusion. Three-month use of Reduxin Forte in patients with grade I obesity, who planned IVF, improved anthropometric parameters, normalized carbohydrate metabolism, and decreased 8-0HdG levels. Pregnancy after VF and in a natural cycle occurred in 8/18 (44.4%) and 8/26 (30.7%) of women, respectively.

全文:

受限制的访问

作者简介

Tamara Zhuk

Altai State Medical University, Ministry of Health of the Russian Federation; Siberian Institute of Human Reproduction and Genetics

Svetlana Yavorskaya

Altai State Medical University, Ministry of Health of the Russian Federation

Vyacheslav Vostrikov

Siberian Institute of Human Reproduction and Genetics

Email: wkoctar@mail.ru

Vladimir Nagaitsev

Siberian Institute of Human Reproduction and Genetics

Email: ivfaltai@mail.ru

Alexey Kotov

Siberian Institute of Human Reproduction and Genetics

Email: 501077@bk.ru

参考

  1. Correa A., Marcinkevage J. Prepregnancy obesity and the risk of birth defects: an update. Nutr Rev. 2013; 71(Suppl. 1): 68-77. doi: 10.1111/nure.12058.
  2. Dolin C.D., Kominiarek M.A. Pregnancy in women with obesity. Obstet Gynecol Clin North Am. 2018; 45: 217-32. http://dx.doi.org/10.1016/j.ogc.2018.01.005
  3. Sneed M.L., Uhler M.L., Grotjan H.E., et al. Body mass index: impact on IVF success appears age-related. Hum Reprod. 2008; 23(8): 1835-9. https://doi. org/10.1093/humrep/den188
  4. Poston L., Caleyachetty R., Cnattingius S., Corvalan C., Uauy R., Herring S., et al. Preconceptional and maternal obesity: epidemiology and health consequences. Lancet Diabetes Endocrinol.2016; 4(12): 1025-1036. doi: 10.1016/S2213-8587(16)30217-0.
  5. Rasmussen S.A., Chu S.Y., Kim S.Y., Schmid C.H., Lau J. Maternal obesity and risk of neural tube defects: a metaanalysis. Am. J. Obstet. Gynecol. 2008; 198(6): 611-9. doi: 10.1016/j.ajog.2008.04.021.
  6. Poston L., Caleyachetty R., Cnattingius S., Corvalan C., Uauy R., Herring S., et al. Preconceptional and maternal obesity: epidemiology and health consequences. Lancet Diabetes Endocrinol. 2018; 4: 1025-36. doi: 10.1016/ S2213-8587(16)30217-0.
  7. Most J., Marlatt K. L., Altazan A. D., Redman L. M. Advances in assessing body composition during pregnancy. Eur J. Clin Nutr. 2018; 72: 645-56. doi: 10.1038/s41430-018-0152-8.
  8. Bozkurt L., Gobl C. S., Hormayer A.T., Luger A., Pacini G., Kautzky-Willer A. The impact of preconceptional obesity on trajectories of maternal lipids during gestation. Sci. Rep.2016; 6: 29971. doi: 10.1038/srep29971.
  9. Burton G.J., Jauniaux E. Oxidative stress. Best Practice & Research Clinical Obstetrics & Gynaecology. 2011; 25(3): 287-99. doi: 10.1016/j. bpobgyn.2010.10.016
  10. Alcala M., Sanchez-Vera I., Sevillano J., Herrero L., Serra D., Ramos M.P., et al. Vitamin E. reduces adipose tissue fibrosis, inflammation, and oxidative stress and improves metabolic profile in obesity. Obesity. 2015; 23(8): 1598-1606. doi: 10.1002/oby.21135
  11. Agarwal A., Aziz N., Rizk B. Studies on Women’s Health. HumanaPress, NewYork; 2013; 33-60. doi:https://doi.org/10.1007/978-1-62703-041-0.
  12. Matsuda M., Shimomura I. Increased oxidative stress in obesity: implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer. Obes. Res. Clin. Pract. 2013; 7: 330-341. doi: 10.1016/j.orcp.2013.05.004
  13. Agarwal A., Aponte-Mellado A., Premkumar B.J., et al. The effects of oxidative stress on female reproduction: a review. Reprod Biol Endocrinol. 2012; 10(1): 49. doi: 10.1186/1477-7827-10-49.
  14. Savini I., Catani M.V., Evangelista D., Gasperi V., Avigliano L. Obesity-associated oxidative stress: strategies finalized to improve redox state. Int. J. Mol. Sci. 2013; 14: 10497-538. doi: 10.3390/ijms140510497.
  15. Alcala M., Calderon-Dominguez M., Serra D., Herrero L., Ramos M.P., Viana M. Short-term vitamin E. treatment impairs reactive oxygen species signaling required for adipose tissue expansion, resulting in fatty liver and insulin resistance in obese mice. PLoS One 2017; 23-56. https://doi.org/10.1371/ journal.pone.0186579
  16. Wu F., Tian F.J., Lin Y. Oxidative stress in placenta: health and diseases. Biomed. Res. Int. 2015; 293271. https://doi.org/10.1155/2015/293271
  17. Malti N., Merzouk H., Merzouk S.A., Loukidi B., Karaouzene N., Malti A., et al. Oxidative stress and maternal obesity: feto-placental unit interaction. Placenta 2014; 35: 411-6. doi: 10.1016/j.placenta.2014.03.010.
  18. ck C.Y., Kim E.H., Choi D.J., Lee H.J., Hahm K.B., Chung M.H. 8-Hydroxydeoxyguanosine: not mere biomarker for oxidative stress, but remedy for oxidative stress-implicatedgastrointestinal diseases. World J. Gastroenterol. 2012; 18(4): 302-8. doi: 10.3748/wjg.v18.i4.302.
  19. Nguyen D.M., El-Serag H.B. The epidemiology of obesity. Gastroenterol Clin North Am. 2010; 39(1):1-7. https://doi.org/10.1016/ j.gtc.2009.12.014
  20. Дедов И.И., Романцова Т.И., Шестакова М.В. Рациональный подход к терапии пациентов с СД2 и ожирением: итоги всероссийской наблюдательной программы «АВРОРА» Ожирение и метаболизм. 2018; 15(4): 48-58.
  21. Востриков В.В., Маркова Е.А., Кузнецова Т.А., Елизарьев А.Ю. Этиология и патогенез синдрома гиперстимуляции яичников. Современные аспекты диагностики, лечения и профилактики. Барнаул: Алтайский медицинский университет, 2016. 60 с.
  22. Иванова А.Р. Меди ко-психологические особенности женщин во время лечения бесплодия: автореф. дис. канд. мед. наук. М., 2010.
  23. Жук Т.В., Яворская С.Д., Востриков В.В., Немцева Г.В. Прогноз эффективности экстракорпорального оплодотворения у пациенток с трубно-перитонеальным бесплодием и ожирением. Российский вестник акушера-гинеколога. 2019; 19(1): 66-9. doi: 10.17116/rosakush20191901166

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##